Patent · US Active

Triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase

US9920075B2 · kind B2 · utility

1Cited by

0References

9Claims

0Family size

Assignee

Bristol-Myers Squibb Company · US

Inventors

Nicholas R. Wurtz · Pennington, US
Andrew Q. Viet · Schwenksville, US
Scott A. Shaw · Lawrence, US
Benjamin P. Vokits · Kingston, US
Ellen K. Kick · Pennington, US
Meriah Neissel Valente · Somerville, US
Andrew K. Dilger · Princeton, US
Kumar Balashanmuga Pabbisetty · Piscataway, US
Sutjano Jusuf · Ardmore, US

Key dates

Filing date	Sep 9, 2015
Grant date	Mar 20, 2018
Priority date	—
Expiry date	Sep 9, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D487/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides compounds of Formula (I): wherein A and R1 are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.